The three reasons people start looking
Price against usage
Enterprise pricing assumes an enterprise testing function.
If yours shrank, the cost per useful run rises quietly.
No dedicated QA
Low-code platforms are built for testers to author flows.
With no testers, nobody is authoring, and the platform idles.
Maintenance creep
Self-healing helps and does not remove the work of keeping a suite meaningful.
Somebody is still deciding what should be covered.
Only the first is really about Mabl. The other two are about whether any author-first platform fits a team that no longer has authors.
What a Mabl alternative should be compared on
| Dimension | Author-first platforms | TestSprite |
|---|---|---|
| Who creates tests | A person builds each flow in the editor | Generated from your sources, refined in natural language |
| Who runs them | Scheduled, or triggered by a person | Triggered by the change, including from a coding agent |
| What a failure returns | A report for a human to read | A bundle a coding agent can act on directly |
| Fit with AI-written code | Coverage lags behind code volume | Verification sits inside the same loop as the change |
| Who it assumes you have | A testing function | Developers and their agents |
The row that matters most is the third. If the output of a failing test is a report someone has to interpret, a team without testers has bought a report nobody reads.
Questions worth asking any candidate
Who writes the two hundredth test? The first ten get written during the trial by someone motivated. Ask about the rest.
What happens when a run does not reach its assertions? If that reports as a pass, the whole thing is decorative. This is worth testing deliberately.
Can the fixer start from the failure output? Increasingly the fixer is an agent, which cannot interpret a screenshot.
Before you migrate anything
Migration is expensive and often unnecessary. Run a candidate alongside for a few weeks on the flows you care about most. If the new coverage is genuinely finding things, the decision makes itself, and if it is not you have lost a few weeks rather than a quarter.
How to evaluate any of them
Break something on purpose. Introduce a real regression, like a save that no longer persists, and watch what each candidate reports. Does it fail, does the failure name the actual divergence, and could whoever fixes it start from that output without re-deriving the story. A tool that reports a pass on a run which never reached its assertions has failed the only test that matters.
The question that saves a quarter
Before evaluating anything, work out whether your problem is the platform or the staffing. The two look identical from inside and lead to completely different decisions.
A useful test: look at when coverage stopped growing and check what else happened that month. If it coincides with someone leaving, changing role, or being pulled onto a project, the platform was never the issue and switching will reproduce the outcome with a new logo and a migration cost on top.
If coverage stopped growing while the same people were still there and still trying, that is a tool problem and worth acting on. That distinction takes an afternoon to establish and it is the difference between a productive evaluation and an expensive one.
Getting started
Terminal
npm install -g @testsprite/testsprite-cli
testsprite setup
The same setup is available in the TestSprite dashboard if you would rather not install anything locally. The rest of the CLI surface is in the CLI repository.
The trigger matters more than the mechanism. Pointing it at your deployment event means every change is checked without anyone deciding to; the GitHub App does that from the dashboard, and a GitHub Actions step does it from inside your workflow.
What TestSprite does differently
It does not assume you have someone whose job is building test flows. Cases are generated from your product and refined in plain language, so coverage grows without an author, which is the specific mismatch that sends most teams looking in the first place.
Runs are triggered by the change rather than by a schedule or a person, including from a coding agent working in the editor. And a failure returns as a bundle that whoever fixes it can act on directly, which matters more each quarter as the fixer is increasingly an agent rather than a human reading a report.
What you get is coverage that keeps pace with a team that ships fast and has no dedicated QA function, without paying for an editor nobody is opening.
Is Mabl a bad tool?
No. It is a mature platform built around a testing function. The mismatch people run into is organizational rather than technical.
Can we migrate our existing tests?
Treat them as a specification of what matters rather than as artifacts to port. The list of flows is the valuable part.
What about the runs we already have history for?
Historical results rarely survive a platform change in any useful form. Plan to keep the old system readable for a while rather than expecting a clean export.
How long should a trial be?
Long enough to include a real release. A trial that never sees a regression has not tested the thing you are buying.
Do we need to choose one?
Not immediately. Running two in parallel on overlapping flows is the cheapest way to learn which one catches what.
Work out which of the three reasons is yours.
A Mabl alternative search is usually driven by price, by a QA function that no longer exists, or by maintenance. Compare on who writes the two hundredth test and on whether a failure is usable by whoever fixes it, and run a candidate in parallel before migrating anything.